Alchemab Therapeutics
PrivateLast Round
Series A
Extension
Jul 9, 2026
Total Funding Raised
$116M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Alchemab Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A Extension round in September 2025.
Alchemab Therapeutics is a biotechnology company that develops novel therapeutic antibodies by analyzing patient antibody repertoires from disease-resilient individuals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alchemab Therapeutics Comparables
Compare Alchemab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoResponse | 78% | |
| Macomics | 75% | |
| Mestag Therapeutics | 71% |
For institutional investors. Book with your work email.
Alchemab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 9, 2026 | ||||
| Series A Extension | Sep 9, 2025 | ||||
| Grant | Dec 16, 2022 | ||||
| Series A | Apr 15, 2021 | ||||
| Accelerator | May 12, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alchemab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A Extension, Series A |
| SV Health Investors | Series A, Series A Extension, Seed |
| DCVC Bio | Seed, Series A Extension |
| Camford Capital | Series A |
| Lightstone Ventures | Series A, Series A Extension |
| British Business Bank | Series A Extension |
| Innovate UK | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 60% MoM, reaching 4.6K.
- Jul 9, 2026
$34M round led by British Business Bank.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 10, 2026
Alchemab appoints Dr Ben Porter-Brown as Chief Medical Officer to accelerate clinical development of its antibody therapeutics pipeline, effective Sep 10th '26, in the United Kingdom.
For institutional investors. Book with your work email.
Alchemab Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alchemab Therapeutics's valuation, stock price, and market status.
Is Alchemab Therapeutics a public or private company?
Alchemab Therapeutics is a private company.
What is the current stock price of Alchemab Therapeutics?
Alchemab Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alchemab Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alchemab Therapeutics worth (valuation)?
Valuation information for Alchemab Therapeutics is not publicly available.
Can I buy Alchemab Therapeutics stock?
Alchemab Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alchemab Therapeutics's last funding round?
Alchemab Therapeutics's most recent funding round was Series A Extension on July 9, 2026.
Who are the main investors in Alchemab Therapeutics?
Key investors in Alchemab Therapeutics include RA Capital Management, SV Health Investors, British Business Bank.
Will Alchemab Therapeutics IPO soon?
No public IPO plans have been announced for Alchemab Therapeutics.
How can I track Alchemab Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alchemab Therapeutics's shares on secondary markets.